by Noah Blaine

Pfizer Presents New Evidence of IBRANCE® (palbociclib) Effectiveness in HR+, HER2- Metastatic Breast Cancer Patients in Four Real-World Studies at ESMO Congress 2019

First-of-its-kind comparative analysis of real-world data in the CDK 4/6 inhibitor class supports benefits of IBRANCE combination therapy initially shown in clinical trials

source https://finance.yahoo.com/news/pfizer-presents-evidence-ibrance-palbociclib-120000420.html?.tsrc=rss

Leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.